{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:57:53Z","timestamp":1777417073975,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2000,3,1]],"date-time":"2000-03-01T00:00:00Z","timestamp":951868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2000,3]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To report the development of severe thrombocytopenia during alatrofloxacin therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY:<\/jats:title>\n                    <jats:p>\n                      A 54-year-old Native American woman was admitted for pneumonia after completing a 10-day course of loracarbef 200 mg po bid. On admission, the woman was hypoxic (PO\n                      <jats:sub>2<\/jats:sub>\n                      56 mm Hg) and had a platelet count of 408 times 10\n                      <jats:sup>3<\/jats:sup>\n                      \/mm\n                      <jats:sup>3<\/jats:sup>\n                      . Alatrofloxacin 300 mg iv piggyback qd was initiated in the emergency department. The patient's condition gradually improved during the next three days. While preparing for discharge on hospital day 4, the patient developed epistaxis that lasted approximately three hours. Laboratory testing revealed a platelet count of 7 times 10\n                      <jats:sup>3<\/jats:sup>\n                      \/mm\n                      <jats:sup>3<\/jats:sup>\n                      ; stable red blood cell count, hemoglobin, and hematocrit values; and a normal white blood cell count. Alatrofloxacin therapy was discontinued and azithromycin was initiated on hospital day 4. Methylprednisolone 125 mg iv piggyback every 12 hours was initiated on hospital day 5. The platelet count fell to 2 times10\n                      <jats:sup>3<\/jats:sup>\n                      \/mm\n                      <jats:sup>3<\/jats:sup>\n                      on hospital day 5 and then began to rise, reaching 60 times 10\n                      <jats:sup>3<\/jats:sup>\n                      \/mm\n                      <jats:sup>3<\/jats:sup>\n                      when the patient was discharged on hospital day 8.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>Numerous infectious, disease-related, environmental, and pharmacologic factors may cause thrombocytopenia. Drug-induced thrombocytopenia usually develops during the first two weeks of therapy and resolves within one week of drug discontinuation. Thrombocytopenia occurred in &lt;1% of more than 7000 patients receiving alatrofloxacin or trovafloxacin during clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>The time course of this patient's development of and recovery from thrombocytopenia suggests that it was induced by alatrofloxacin. Clinicians should monitor patients receiving alatrofloxacin or trovafloxacin for signs and symptoms of bleeding and thrombocytopenia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.19224","type":"journal-article","created":{"date-parts":[[2003,6,3]],"date-time":"2003-06-03T16:37:47Z","timestamp":1054658267000},"page":"330-334","source":"Crossref","is-referenced-by-count":21,"title":["Severe Thrombocytopenia Associated with Alatrofloxacin"],"prefix":"10.1177","volume":"34","author":[{"given":"Barry J","family":"Gales","sequence":"first","affiliation":[{"name":"Barry J Gales PharmD, Associate Professor of Pharmacy Practice, Southwestern Oklahoma State University, Weatherford, OK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie B","family":"Sulak","sequence":"additional","affiliation":[{"name":"Laurie B Sulak BscPharm, at time of writing, Student, School of Pharmacy, Southwestern Oklahoma State University; now, Staff Pharmacist, Albertson's Pharmacy, Waco, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2000,3,1]]},"reference":[{"key":"bibr1-aph.19224","volume-title":"Trovan (trovafloxacin)","year":"1998"},{"key":"bibr2-aph.19224","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17460"},{"key":"bibr3-aph.19224","volume-title":"Trovan public health advisory","author":"Lumpkin MM","year":"1999"},{"key":"bibr4-aph.19224","first-page":"1889","volume-title":"Hematology","author":"Warkentin TE","year":"1995"},{"key":"bibr5-aph.19224","first-page":"1329","volume-title":"Wintrobe's clinical hematology","author":"Bithell TC","year":"1993"},{"key":"bibr6-aph.19224","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-11_Part_1-199812010-00009"},{"key":"bibr7-aph.19224","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198904133201505"},{"key":"bibr8-aph.19224","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr9-aph.19224","volume-title":"Ambien (zolpidem)","year":"1997"},{"key":"bibr10-aph.19224","doi-asserted-by":"publisher","DOI":"10.1016\/0163-4453(93)95106-S"},{"key":"bibr11-aph.19224","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.1997.tb00013.x"},{"key":"bibr12-aph.19224","doi-asserted-by":"publisher","DOI":"10.1016\/S0750-7658(05)80800-7"},{"key":"bibr13-aph.19224","first-page":"419","volume":"47","author":"Chichmanian RM","year":"1992","journal-title":"Therapie"},{"key":"bibr14-aph.19224","first-page":"410","volume":"46","author":"Lehmann M","year":"1991","journal-title":"Therapie"},{"key":"bibr15-aph.19224","first-page":"1978","volume":"16","author":"Chamouard P","year":"1987","journal-title":"Presse Med"},{"key":"bibr16-aph.19224","first-page":"1660","volume":"141","author":"Wensing JW","year":"1997","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"key":"bibr17-aph.19224","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/26.suppl_B.215"},{"key":"bibr18-aph.19224","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.4.795"},{"key":"bibr19-aph.19224","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1996.tb03648.x"},{"key":"bibr20-aph.19224","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/34.1.7"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.19224","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.19224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:03:11Z","timestamp":1777374191000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.19224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,3]]}},"alternative-id":["10.1345\/aph.19224"],"URL":"https:\/\/doi.org\/10.1345\/aph.19224","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3]]}}}